Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)

OBJECTIVES: The objective of this study was to investigate the expression level of CD40 and its role in the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with rituximab-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). DESIGN AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Guoqi, Ni, Huiyun, Zou, Linqing, Wang, Shukui, Tian, Fuliang, Liu, Hong, Cho, William C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922817/
https://www.ncbi.nlm.nih.gov/pubmed/27382316
http://dx.doi.org/10.2147/OTT.S96992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922817/
https://www.ncbi.nlm.nih.gov/pubmed/27382316
http://dx.doi.org/10.2147/OTT.S96992

Ejemplares similares